Liquidia Technologies (LQDA) AI Stock Analysis

556 Followers

Top Page

Liquidia Technologies

(NASDAQ:LQDA)

58Neutral

Liquidia Technologies has potential upside with promising drug developments and strategic partnerships, but faces significant financial risks due to declining revenues, high leverage, and consistent losses. Technical indicators show mixed signals with medium-term strength but short-term volatility. While the earnings call highlighted strategic positives, declining revenue and increased losses remain concerns.

Positive Factors

Clinical Efficacy

Interim data from ASCENT further underscores Yutrepia’s clinical benefits, showing a meaningful improvement in 6-minute walk distance, supporting evidence that higher treprostinil doses translate to better patient outcomes.

Market Opportunity

The PAH/PH-ILD market opportunity presents significant growth potential for Liquidia Technologies.

Regulatory Approval

A transformative period is approaching for Liquidia Technologies due to the forthcoming PDUFA date for the approval of Yutrepia in PAH and PH-ILD.

Negative Factors

Legal Challenges

The final legal obstacle for Yutrepia is likely the cross-claim UTHR raised in a lawsuit, but there are low odds of success for UTHR on the challenge.

Tariff Impact

Potential impact of tariffs was discussed as a factor that could influence Liquidia Technologies.

Liquidia Technologies (LQDA) vs. S&P 500 (SPY)

Market Cap

$1.17B

Dividend YieldN/A

Average Volume (3M)1.12M

Price to Earnings (P/E)―

Beta (1Y)1.16

Revenue Growth-19.97%

EPS Growth-37.22%

CountryUS

Employees170

SectorHealthcare

Sector Strength72

IndustryBiotechnology

Share Statistics

EPS (TTM)-1.66

Shares Outstanding85,298,540

10 Day Avg. Volume1,542,961

30 Day Avg. Volume1,122,768

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)92.15

Price to Cash Flow (P/CF)-15.50

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$27.63

Price Target Upside101.38% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Liquidia Technologies Business Overview & Revenue Model

Company DescriptionLiquidia Technologies, Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies using its proprietary PRINT technology. The company is primarily engaged in the healthcare sector, with a particular emphasis on developing therapies for the treatment of pulmonary arterial hypertension (PAH) and other diseases. Its core product, YUTREPIA (treprostinil) inhalation powder, is designed to improve the treatment of PAH by providing a more efficient delivery mechanism for medication.

How the Company Makes MoneyLiquidia Technologies generates revenue through the commercialization of its pharmaceutical products, primarily focusing on the sales of YUTREPIA, which is intended for the treatment of pulmonary arterial hypertension. The company aims to capture market share in the PAH treatment space by offering a differentiated product that leverages its PRINT technology to enhance drug delivery efficiency. Additionally, Liquidia may engage in strategic partnerships, collaborations, or licensing agreements with other pharmaceutical companies to expand its market reach and product offerings, thereby potentially creating additional revenue streams.

Liquidia Technologies Financial Statement Overview

Summary

Liquidia Technologies faces challenges with declining revenues and consistent losses impacting profitability and equity. The company's liquidity position is strong due to cash reserves, but high leverage poses financial risks. Efforts to raise funds through financing are helping maintain liquidity.

Income Statement

Neutral

Liquidia Technologies shows a declining revenue trend with Total Revenue decreasing by 20% from 2023 to 2024. Gross Profit Margin stands at 58%, indicating good cost management relative to revenue. However, the company has been consistently unprofitable with a negative Net Profit Margin due to high operating expenses, as seen in the negative EBIT and EBITDA margins.

Balance Sheet

Negative

The company has a high debt-to-equity ratio due to negative equity, indicating high leverage and potential financial risk. On a positive note, the company has significant cash reserves compared to its total liabilities, suggesting liquidity strength. However, negative stockholders' equity reflects accumulated losses.

Cash Flow

Neutral

Operating cash flow is negative, indicating the company is not generating cash from operations. The free cash flow has further deteriorated due to higher capital expenditures. Despite negative cash flows, the company raised significant funds through financing activities, which is a positive aspect for liquidity.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
14.00M	17.49M	15.94M	12.85M	739.63K
	Gross Profit
8.12M	14.60M	13.08M	9.83M	501.92K
	EBIT
-121.29M	-73.38M	-38.77M	-33.80M	-59.09M
	EBITDA
-115.71M	-70.05M	-34.72M	-27.91M	-55.79M
	Net Income Common Stockholders
-130.39M	-78.50M	-38.37M	-29.78M	-57.49M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
176.48M	83.68M	93.28M	57.49M	65.32M
	Total Assets
230.31M	118.33M	129.20M	93.73M	99.53M
	Total Debt
25.02M	3.50M	24.46M	16.08M	17.14M
	Net Debt
-151.46M	-80.18M	-68.82M	-41.42M	-48.17M
	Total Liabilities
153.04M	71.04M	38.78M	28.46M	28.45M
	Stockholders Equity
77.28M	47.29M	-350.60M	-309.58M	-275.00M
Cash Flow		Free Cash Flow
-98.37M	-42.85M	-29.18M	-34.14M	-54.90M
	Operating Cash Flow
-93.42M	-41.56M	-28.59M	-34.04M	-54.14M
	Investing Cash Flow
-8.44M	-11.29M	-587.00K	-107.22K	247.91K
	Financing Cash Flow
194.66M	43.25M	64.96M	26.32M	63.42M

Liquidia Technologies Technical Analysis

Technical Analysis Sentiment

Positive

Last Price13.72

Price Trends

50DMA

14.84

Negative

100DMA

13.51

Positive

200DMA

12.18

Positive

Market Momentum

MACD

-0.38

Negative

RSI

47.37

Neutral

STOCH

83.02

Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LQDA, the sentiment is Positive. The current price of 13.72 is below the 20-day moving average (MA) of 14.01, below the 50-day MA of 14.84, and above the 200-day MA of 12.18, indicating a neutral trend. The MACD of -0.38 indicates Negative momentum. The RSI at 47.37 is Neutral, neither overbought nor oversold. The STOCH value of 83.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LQDA.

Liquidia Technologies Risk Analysis

Liquidia Technologies disclosed 61 risk factors in its most recent earnings report. Liquidia Technologies reported the most risks in the “Tech & Innovation” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Liquidia Technologies Peers Comparison

Overall Rating

UnderperformOutperform

Sector (50)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	70 Outperform	$1.06B	198.70	1.52%	―	33.97%	―
ARDX	60 Neutral	$1.10B	―	-23.01%	―	168.06%	44.66%
LQDA	58 Neutral	$1.17B	―	-209.35%	―	-19.97%	-37.22%
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%
OCUL	46 Neutral	$1.14B	―	-95.21%	―	9.03%	-25.00%
CLDX	43 Neutral	$1.18B	―	-26.84%	―	1.99%	15.95%
NVAX	34 Underperform	$1.03B	―	30.06%	―	-30.65%	77.62%

* Healthcare Sector Average

Performance Comparison

LQDA

Liquidia Technologies

13.72

0.43

3.24%

CLDX

Celldex

18.30

-19.68

-51.82%

NVAX

Novavax

6.00

2.03

51.13%

ARDX

Ardelyx

4.82

-1.66

-25.62%

OCUL

Ocular Therapeutix

7.31

2.09

40.04%

AUPH

Aurinia Pharmaceuticals

7.75

2.76

55.31%

Liquidia Technologies Earnings Call Summary

Earnings Call Date: Mar 19, 2025 | % Change Since: -6.92% | Next Earnings Date: May 8, 2025

Earnings Call Sentiment Neutral

The earnings call presented a mixed sentiment. While there were significant strategic advancements and promising clinical trial results, financial challenges and a decrease in revenue were also highlighted.

Highlights

Strategic Imperatives for Growth

Liquidia is focusing on four strategic imperatives including the launch of YUTREPIA for PAH and PH-ILD, advancing its clinical profile, capturing market share, and advancing treatment options with L606.

Positive ASCENT Trial Results

The ASCENT trial demonstrated an improvement in the six-minute walk test by 26.4 meters at week eight, surpassing the 16 meters at week eight observed in the TYVASO Phase III trial.

Strong Partnership with HealthCare Royalty Partners

Liquidia expanded its financing agreement with HealthCare Royalty Partners, securing up to $100 million in additional financing.

Lowlights

Decrease in Revenue

Revenue decreased from $17.5 million in 2023 to $14 million in 2024, primarily due to lower sales quantities driven by limitations on the availability of pumps for treprostinil injections.

Increased Net Loss

Net loss for 2024 increased to $130.4 million from $78.5 million in 2023, driven by increased R&D expenses and legal fees related to YUTREPIA litigation.

Company Guidance

During the 2024 financial results and corporate update call, Liquidia Corporation provided guidance on several key metrics and strategic objectives for 2025. The company anticipates a transformational year, driven by the potential final approval and launch of YUTREPIA for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) after gaining clinical exclusivity on May 23, 2025. Liquidia aims to secure a strong market position by highlighting YUTREPIA's best-in-class inhaled prostacyclin profile, targeting dose levels three times higher than the therapeutic target of nebulized TYVASO. Additionally, they reported promising results from the ASCENT trial, including a mean improvement of 26.4 meters in the six-minute walk test at week eight. Financially, Liquidia expanded its financing agreement with HealthCare Royalty Partners to potentially provide up to $100 million, supporting the planned launch and ongoing developments, with the goal of reaching profitability without additional capital needs. During 2024, the company reported $14 million in revenue, a decrease from the previous year, and a net loss of $130.4 million. Research and development expenses increased to $47.8 million, driven by investments in the L606 program and YUTREPIA research. General and administrative expenses also rose significantly to $81.6 million, reflecting personnel and legal costs associated with YUTREPIA-related litigation.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.